γδ T cells BiTE back at small cell lung cancer.

γδ T cell-engaging BiTEs demonstrate potent activity against small cell lung cancer, overcoming limitations of traditional CD8+ T cell responses.

• Why it matters: Small cell lung cancer often resists checkpoint blockade therapy due to low MHC-I expression and ineffective CD8+ T cell activation, creating a need for alternative immunotherapies.
• What they did: Ng et al. characterized cytotoxic γδ T cells in small cell lung cancer and used a bispecific T cell engager targeting Vδ2+ cells to bypass MHC-I dependence.
• The result: This approach effectively activates γδ T cells to attack tumor cells, offering a promising strategy to improve immunotherapy outcomes in resistant small cell lung cancer.